Filing Flows › Cartesian Therapeutics (RNAC) › Q4 2025
Cartesian Therapeutics (RNAC) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 9, 2026
Cartesian Therapeutics (RNAC) reported revenue of $947K for the fourth quarter 2025 (Q4 2025) and +110% from the quarter before.
Cartesian Therapeutics, Q4 2025: revenue $947K, net loss $92.6M, operating cash flow −$17.7M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $947K | +110% | — |
| Operating profit | −$78.6M | — | — |
| Net earnings | −$92.6M | — | — |
| Operating cash flow | −$17.7M | — | — |
What changed
Revenue was $947K in Q4 2025, up 110% from the previous quarter.
Operating costs exceeded revenue by $78.6M, an operating margin of -8304.0%. The quarter ended with a net loss of $92.6M, wider than the previous quarter's $35.9M loss.
Operating cash flow was −$17.7M. Non-cash charges added back $600K of depreciation and $2.1M of share-based compensation. Working capital and other items added $72.1M. Capital expenditures of $492K exceeded it, leaving free cash flow of −$18.2M.
Questions
What was Cartesian Therapeutics' revenue in the fourth quarter 2025?
Cartesian Therapeutics (RNAC) reported revenue of $947K for the fourth quarter 2025 (Q4 2025) and +110% from the quarter before.